Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

John T. Leith, Shaker A. Mousa, Aleck Hercbergs, Hung Yun Lin, Paul J. Davis

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

Original languageEnglish
Pages (from-to)37069-37075
Number of pages7
JournalOncotarget
Volume9
Issue number97
Publication statusPublished - Dec 1 2018

Fingerprint

Thyroid Hormones
Integrins
Neoplasms
Thyroid Hormone Receptors
Radiation Tolerance
Thyroxine
Signal Transduction

Keywords

  • AKT
  • Epithelial-mesenchymal transition (EMT)
  • Integrin open configuration
  • L-thyroxine (T)
  • STAT3

ASJC Scopus subject areas

  • Oncology

Cite this

Leith, J. T., Mousa, S. A., Hercbergs, A., Lin, H. Y., & Davis, P. J. (2018). Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. Oncotarget, 9(97), 37069-37075.

Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. / Leith, John T.; Mousa, Shaker A.; Hercbergs, Aleck; Lin, Hung Yun; Davis, Paul J.

In: Oncotarget, Vol. 9, No. 97, 01.12.2018, p. 37069-37075.

Research output: Contribution to journalReview article

Leith, JT, Mousa, SA, Hercbergs, A, Lin, HY & Davis, PJ 2018, 'Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone', Oncotarget, vol. 9, no. 97, pp. 37069-37075.
Leith JT, Mousa SA, Hercbergs A, Lin HY, Davis PJ. Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. Oncotarget. 2018 Dec 1;9(97):37069-37075.
Leith, John T. ; Mousa, Shaker A. ; Hercbergs, Aleck ; Lin, Hung Yun ; Davis, Paul J. / Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. In: Oncotarget. 2018 ; Vol. 9, No. 97. pp. 37069-37075.
@article{ed8ff2a5e578428f8b6c5ab546e32649,
title = "Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone",
abstract = "Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.",
keywords = "AKT, Epithelial-mesenchymal transition (EMT), Integrin open configuration, L-thyroxine (T), STAT3",
author = "Leith, {John T.} and Mousa, {Shaker A.} and Aleck Hercbergs and Lin, {Hung Yun} and Davis, {Paul J.}",
year = "2018",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "37069--37075",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "97",

}

TY - JOUR

T1 - Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

AU - Leith, John T.

AU - Mousa, Shaker A.

AU - Hercbergs, Aleck

AU - Lin, Hung Yun

AU - Davis, Paul J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

AB - Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

KW - AKT

KW - Epithelial-mesenchymal transition (EMT)

KW - Integrin open configuration

KW - L-thyroxine (T)

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=85058321734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058321734&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85058321734

VL - 9

SP - 37069

EP - 37075

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 97

ER -